Presentation
14 March 2023 Optimizing photobiomodulation in the in vitro and in vivo models towards effective therapy of Alzheimer's disease (Conference Presentation)
Author Affiliations +
Proceedings Volume 12380, Biophotonics and Immune Responses XVIII; 1238009 (2023) https://doi.org/10.1117/12.2651226
Event: SPIE BiOS, 2023, San Francisco, California, United States
Abstract
A significant amount of recent studies reported use of photobiomodulation (PBM) to slow down the progression of Alzheimer’s disease. Less reports on improving the PBM therapeutic efficiency by optimizing light parameters. Our findings demonstrate that PBM effect in in vitro and in vivo AD models significantly depends on wavelength, dose and mode (continuous wave or pulsed) of irradiation. While the viability and anti-inflammatory activity of amyloid-β (Aβ) treated cultured neurons and microglia were improved after irradiation with 808 nm light, Aβ plagues accumulation and cerebral amyloid angiopathy in the AD mice brain were best attenuated after stimulation with 40 Hz pulsed 808 nm or spectrally broad visible light, which also improved spatial learning and memory abilities.Future research can involve simultaneous or sequential stimulation with visible and NIR pulsed light in optimize wavelengths, dose and frequencies to achieve efficient AD therapy.
Conference Presentation
© (2023) COPYRIGHT Society of Photo-Optical Instrumentation Engineers (SPIE). Downloading of the abstract is permitted for personal use only.
Hao Xu, Tymish Y. Ohulchanskyy, and Junle Qu "Optimizing photobiomodulation in the in vitro and in vivo models towards effective therapy of Alzheimer's disease (Conference Presentation)", Proc. SPIE 12380, Biophotonics and Immune Responses XVIII, 1238009 (14 March 2023); https://doi.org/10.1117/12.2651226
Advertisement
Advertisement
KEYWORDS
In vitro testing

In vivo imaging

Alzheimer's disease

Light emitting diodes

Microscopy

Luminescence

Near infrared

Back to Top